Results 21 to 30 of about 256,813 (405)

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

American Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter, Alexis A. Thompson, Francis J. Pierciey Jr, Matthew Hsieh, Naoya Uchida, Philippe Leboulch, Manfred Schmidt, Melissa Bonner, Ruiting Guo, Alex Miller, Jean‐Antoine Ribeil, David Davidson, Mohammed Asmal, Mark C. Walters, John F. Tisdale   +14 more
wiley   +1 more source

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

, 2020
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia . Because of the poor prognosis associated with FMS-like tyrosine kinase 3 internal tandem duplication mutated Acute myeloid leukemia, allogeneic ...
Abou Dalle, Iman, Aljurf, Mahmoud, Baron, Frederic, Bazarbachi, Ali, Brissot, Eolia, Bug, Gesine, Ciceri, Fabio, Döhner, Hartmut, Esteve, Jordi, Floisand, Yngvar, Giebel, Sebastian, Gilleece, Maria, Gorin, Norbert-Claude, Jabbour, Elias, Kantarjian, Hagop, Kharfan Dabaja, Mohamed, Labopin, Myriam, Lanza, Francesco, Malard, Florent, Mohty, Mohamad, Nagler, Arnon, Peric, Zinaida, Prebet, Thomas, Ravandi, Farhad, Ruggeri, Annalisa, Sanz, Jaimie, Savani, Bipin N, Schmid, Christoph, Shouval, Roni, Spyridonidis, Alexandros, Versluis, Jurjen, Vey, Norbert   +31 more
core   +7 more sources

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

American Journal of Hematology, Volume 98, Issue 1, Page 193-209, January 2023., 2023
Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox   +2 more
wiley   +1 more source

Immune Reconstitution in the Aging Host: Opportunities for Mechanism-Based Therapy in Allogeneic Hematopoietic Cell Transplantation

Frontiers in Immunology, 2021
Older patients with hematologic malignancies are increasingly considered for allogeneic hematopoietic cell transplantation with encouraging outcomes.
Richard J. Lin, Richard J. Lin, Harold K. Elias, Harold K. Elias, Marcel R. M. van den Brink, Marcel R. M. van den Brink   +5 more
doaj   +1 more source

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

American Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Péter Reményi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kröger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha, on behalf of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +25 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

Journal of Clinical Oncology, 2020
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently ...
A. Burchert, G. Bug, Lea Fritz, J. Finke, M. Stelljes, C. Röllig, E. Wollmer, R. Wäsch, M. Bornhäuser, T. Berg, F. Lang, G. Ehninger, H. Serve, R. Zeiser, E. Wagner, N. Kröger, C. Wolschke, M. Schleuning, K. Götze, C. Schmid, M. Crysandt, Eva Esseling, D. Wolf, Ying Wang, A. Böhm, C. Thiede, T. Haferlach, Christian Michel, W. Bethge, T. Wündisch, C. Brandts, Susanne Harnisch, M. Wittenberg, H. Hoeffkes, Susanne Rospleszcz, A. Burchardt, A. Neubauer, Markus Brugger, K. Strauch, C. Schade-Brittinger, S. Metzelder   +40 more
semanticscholar   +1 more source

Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs.

PLoS ONE, 2021
The number of Hematopoietic Stem Cell Transplantations has risen in the past 20 years. The practice of outpatient Hematopoietic Stem Cell Transplantation programs is increasing in an attempt to improve the quality of patient care and reduce the demand ...
Marino J González, Elena Urizar, Maider Urtaran-Laresgoiti, Roberto Nuño-Solinís, Esther Lázaro-Pérez, Lourdes Vázquez, Maria Jesús Pascual-Cascón, Carlos Solano, Mi Kwon, Cristina Gallego, Francesc Fernández-Avilés   +10 more
doaj   +1 more source

Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation [PDF]

Frontiers in Immunology, 2020
Autoimmune manifestations after allogeneic hematopoietic stem cell transplantation (AHSCT) are rare and poorly understood due to the complex interplay between the reconstituting immune system and transplant-associated factors. While autoimmune manifestations following AHSCT have been observed in children with graft-versus-host disease (GvHD), an ...
Nataliya P. Buxbaum, Steven Z. Pavletic
openaire   +4 more sources

Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report

Frontiers in Immunology, 2022
The use of chimeric antigen receptor T cells (CAR-Ts) is effective in the treatment of hematological malignancies. It has been reported that HBV is reactivated after CAR-T immunotherapy for refractory/relapsed hematological malignant B-cell tumors ...
Zhihui Li, Fanqiao Meng, Jing Li, Tong Wu   +3 more
doaj   +1 more source